Skip to main content

RA Capital Management — Portfolio, Page 10

Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.

453
Companies
$44.2B
Total invested
$123.1M
Avg. check
30
Industries
Biotechnology 17Therapeutics 13Health Care 11Biopharma 8Pharmaceutical 5Medical 4+24 more
Founder contacts

Verified emails & LinkedIn for founders across this portfolio.

jane@on●●●●●●●.com
linkedin.com/in/●●●●●●
Verified contacts, updated monthly
Get instant access →

Portfolio companies

Showing 217240 of 453
Be Biopharma
January 2025

Be Biopharma develops engineered B cell medicines for serious genetic diseases.

Biopharma · Cambridge$92.0M Series C
Azalea Therapeutics
November 2025

Azalea Therapeutics is a biotechnology company with a primary focus on developing cancer immunotherapies.

Biotechnology · Berkeley$65.0M Series A
Antios Therapeutics
November 2021

Antios Therapeutics is a biopharmaceutical company developing innovative therapies for viral diseases.

Biopharma · Atlanta$75.0M Series B
Verve Therapeutics
November 2023

Verve Therapeutics is a clinical-stage biotechnology company developing genetic medicines for cardiovascular disease.

Biotechnology · Boston$143.8M Post-IPO Equity
Bia Energy
November 2024

Bia Energy is transforming LatAm’s power sector with smart meters and a digital platform for real-time control, savings, and sustainability.

Analytics · Bogotá$8.5M Convertible Note
NanoMosaic
November 2025

NanoMosaic provides solutions for early illness detection, prognostic monitoring, and biomarker identification.

Biopharma · Waltham$3.0M Venture - Series Unknown
Game Play Network, Inc.
January 2023

Game Play Network is a real money gaming platform that offers online racing casino for players.

Casino · Los AngelesVenture - Series Unknown
Lusaris Therapeutics
November 2022

Lusaris Therapeutics develops small-molecule neuroplastogen therapeutics for neuropsychiatric and neurological disorders.

Biotechnology · Boston$60.0M Series A
Sortera Technologies
November 2025

Sortera Alloys manufactures low-cost, high-quality metal alloys for domestic manufacturing using its artificial intelligence technology.

Artificial Intelligence (AI) · Fort Wayne$45.0M Venture - Series Unknown
Cortica
November 2024

Cortica provides neurological therapies for children with autism and other developmental differences.

Health Care · San Diego$80.0M Venture - Series Unknown
Artios Pharma
November 2025

Artios Pharma is a biopharmaceutical company that provides new solutions in the DNA damage response (DDR) field.

Biopharma · Cambridge$115.0M Series D
Invivyd
November 2025

Invivyd develops antibodies to transcend the limitations of the human immune system and fight against viral infections.

Biotechnology · Waltham$125.0M Post-IPO Equity
Jnana Therapeutics
November 2022

Jnana Therapeutics develops innovative therapies using a chemoproteomics drug discovery platform.

Biotechnology · Boston$107.0M Series C
Metsera
November 2024

Metsera is a clinical‐stage biotech firm developing oral & injectable hormone therapies to treat obesity & related metabolic diseases.

Biopharma · New York$215.0M Series B
Biohaven Pharmaceutical
November 2025

Biohaven is a biopharmaceutical company that develops drug candidates targeting neurological diseases.

Biotechnology · New Haven$200.0M Post-IPO Equity
Alentis Therapeutics
November 2024

ALENTIS Therapeutics is a Swiss-French biotech company developing novel therapeutics in advanced liver disease and cancer.

Biotechnology · Allschwil$181.4M Series D
Kinaset Therapeutics
January 2026

Kinaset Therapeutics is a biopharma company that focuses on advancement of novel drugs in areas of unmet medical needs.

Health Care · Boston$103.0M Series B
Affinia Therapeutics
October 2025

Affinia Therapeutics is a biotechnology company developing transformative AAV gene therapies for people with rare and prevalent diseases.

Biotechnology · Waltham$40.0M Series C
TORL BioTherapeutics
October 2025

TORL BioTherapeutics is a clinical-stage biopharmaceutical business.

Biopharma · Culver City$96.0M Series C
Cidara Therapeutics
October 2025

Cidara Therapeutics develops targeted immunotherapies aimed at improving treatment outcomes for patients with serious diseases.

Biotechnology · San Diego$339.0M Grant
Enara Bio
October 2024

Ervaxx is illuminating the immune interface to develop new cancer therapies.

Biopharma · Oxford$32.5M Series B
Forward Therapeutics
October 2023

Forward Therapeutics is a biopharma comapny targeting treatment of chronic inflammatory disorders.

Health Care · Palm Beach Gardens$50.0M Series A
Seres Therapeutics
October 2025

Seres Therapeutics is a microbiome therapeutics company that develops treatments for serious diseases.

Biopharma · Cambridge$3.6M Grant
Cedilla Therapeutics
October 2021

Cedilla Therapeutics is a biotechnology company that develops targeted small molecules for the treatment of cancer and other diseases.

Biotechnology · Cambridge$25.0M Series B

Where RA Capital Management invests

Biotechnology17
Therapeutics13
Health Care11
Biopharma8
Pharmaceutical5
Medical4

About RA Capital Management's portfolio

How many companies has RA Capital Management invested in?

RA Capital Management has invested in 453 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.

What industries does RA Capital Management invest in?

RA Capital Management's top investment sectors include Biotechnology, Therapeutics, Health Care, Biopharma, Pharmaceutical. The firm invests across 30 different industry categories.

What is RA Capital Management's largest investment?

Among tracked funding rounds, Cidara Therapeutics received $339.0M in a Grant round. RA Capital Management's total known invested capital is $44.2B.

What is the average investment size for RA Capital Management?

RA Capital Management's average investment size is $123.1M across its portfolio of 453 companies.

What are RA Capital Management's most recent investments?

Recent RA Capital Management portfolio additions include Be Biopharma, Azalea Therapeutics, Antios Therapeutics, Verve Therapeutics, Bia Energy. These companies were founded in 2020 or later.

Reach the founders behind these 453 companies
Verified emails and LinkedIn profiles, updated monthly.
Get instant access →